AbCellera Biologics Inc vs Prologis Inc — how do they compare? AbCellera Biologics Inc trades at $8.98 (market cap $2.99B), while Prologis Inc trades at $139.1 (market cap $132.57B). The key difference: Prologis Inc is far larger — about 44.3× AbCellera Biologics Inc's market cap, and Prologis Inc pays a 3.07% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PLD | |
|---|---|---|
Market Cap | $2.99B | $132.57B |
Sector | Health | Real Estate |
52-Week High | $9.76 | $149.96 |
52-Week Low | $2.78 | $104.81 |
Enterprise Value | $2.58B | $167.31B |
Dividend Yield | — | 3.07% |
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →